title: The mechanism of melanoma-associated thrombin activity and von Willebrand factor release from endothelial cells.
abstract: Activation of the coagulation system in malignancy enables tumor spreading and is thus associated with poor prognosis for the patient. In this study, we analyzed the in vitro mechanisms by which two human metastatic melanoma cell lines, MV3 and WM9, transform the vascular endothelium into a prothrombotic activated state. We show that both melanoma cell lines activate prothrombin due to tissue factor (TF) expression by showing that thrombin generation was blocked with a TF-neutralizing antibody and TF-siRNA. In addition, using the cysteine protease inhibitor E-64, we excluded the formerly described cancer procoagulant (CP) as a major factor contributing to thrombin generation. Furthermore, we describe a direct thrombin-independent response of endothelial cells (ECs) to MV3-derived supernatant as measured by rapid release of VWF. We also show that two clinically approved LMWHs, tinzaparin and enoxaparin, are effective inhibitors of thrombin generation and thrombin activity in plasma. Furthermore, our data indicate a protective effect of heparins on EC activation as shown by reduced VWF release in response to MV3 supernatant. These promising effects of heparins on the melanoma-induced thrombotic conditions justify further clinical investigations in the field of oncology.
authors.affiliation: Department of Dermatology, Laboratory of Cell Biology, Westfaelische Wilhelms-University of Muenster, Muenster, Germany.
authors.forename: Nina
authors.initials: N
authors.lastname: Kerk
authors.forename: Elwira A
authors.initials: EA
authors.lastname: Strozyk
authors.forename: Birgit
authors.initials: B
authors.lastname: Pöppelmann
authors.forename: Stefan W
authors.initials: SW
authors.lastname: Schneider
mesh_terms: D000925:Anticoagulants / Q000494:pharmacology; D045744:Cell Line, Tumor; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism*; D017984:Enoxaparin / Q000494:pharmacology; D005434:Flow Cytometry; D006493:Heparin / Q000494:pharmacology; D006495:Heparin, Low-Molecular-Weight / Q000494:pharmacology; D006801:Humans; D008545:Melanoma / Q000378:metabolism* / Q000556:secondary; D011516:Prothrombin / Q000378:metabolism*; D034741:RNA, Small Interfering; D012878:Skin Neoplasms / Q000378:metabolism* / Q000473:pathology; D013917:Thrombin / Q000378:metabolism*; D013925:Thromboplastin / Q000235:genetics / Q000378:metabolism; D000078222:Tinzaparin; D014841:von Willebrand Factor / Q000378:metabolism*
chemical_list: D000925:Anticoagulants; D017984:Enoxaparin; D006495:Heparin, Low-Molecular-Weight; D034741:RNA, Small Interfering; D014841:von Willebrand Factor; D000078222:Tinzaparin; D011516:Prothrombin; D006493:Heparin; D013925:Thromboplastin; D013917:Thrombin